Rheumatoid Arthritis | Patient Profiler | US | 2017
Rheumatoid arthritis (RA) treatment is typically initiated with cost-effective conventional DMARDs, such as methotrexate. The U.S. market for conventional DMARD-refractory RA patients is crowded with efficacious biologics, including blockbuster tumor necrosis factor alpha (TNF-alpha) inhibitors Amgen’s Enbrel, AbbVie’s Humira, and Janssen’s Remicade, as well as non-TNF-alpha inhibitors such as Bristol-Myers Squibb’s Orencia, Roche’s/Genentech’s Rituxan and Actemra. In addition, Pfizer’s Jak inhibitor Xeljanz, the first targeted oral molecule approved for RA, has been approved for almost five years in the United States and is gaining steady uptake. The RA market is expected to become increasingly competitive, with upcoming approvals of additional agents and the entry of biosimilars, making brand differentiation and understanding of key patient characteristics ever more critical for marketers.
QUESTIONS ANSWERED
What is the patient share in RA for TNF-alpha inhibitors and other key segments?
What are the demographic characteristics and clinical profiles of RA patients on biologics and Xeljanz?
What are the key risk factors, comorbidities, and co-prescribed/additional therapies by patient segment for RA?
How do RA patient cohorts compare in care utilization and outcomes (physician visits and other healthcare encounters)?
What are the reimbursed and out-of-pocket costs?
What insurance type do RA patients have?
PRODUCT DESCRIPTION
Patient Profiler provides disease-specific, patient-level analysis of key demographic, clinical, and cost-based metrics underlying brand use, all sourced with DRG’s comprehensive Real World Data (RWD) repository.